[18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study
Autonomic involvement, including cardiac denervation, may precede the motor symptoms of Parkinson’s disease by several years. L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine is a positron emitter and a true analog of L-dopa, used in clinical practice to assess striatal dopaminergic integrity. The prese...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2020-09-01
|
| Series: | Journal of Integrative Neuroscience |
| Subjects: | |
| Online Access: | https://jin.imrpress.com/fileup/1757-448X/PDF/1601432747551-43610672.pdf |
| _version_ | 1818006569099460608 |
|---|---|
| author | Jonathan Kuten, Adi Linevitz, Hedva Lerman, Nanette Freedman, Meir Kestenbaum, Tamara Shiner, Nir Giladi, Einat Even-Sapir |
| author_facet | Jonathan Kuten, Adi Linevitz, Hedva Lerman, Nanette Freedman, Meir Kestenbaum, Tamara Shiner, Nir Giladi, Einat Even-Sapir |
| author_sort | Jonathan Kuten, Adi Linevitz, Hedva Lerman, Nanette Freedman, Meir Kestenbaum, Tamara Shiner, Nir Giladi, Einat Even-Sapir |
| collection | DOAJ |
| description | Autonomic involvement, including cardiac denervation, may precede the motor symptoms of Parkinson’s disease by several years. L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine is a positron emitter and a true analog of L-dopa, used in clinical practice to assess striatal dopaminergic integrity. The present study aimed to assess the feasibility of evaluating cardiac sympathetic denervation in Parkinson’s disease patients using L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine positron emission tomography/computed tomography. Patients referred for an L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine positron emission tomography/computed-tomography between July 2015 and May 2017 to evaluate striatal presynaptic dopaminergic integrity underwent a heart positron emission tomography scan following a brain positron emission tomography scan. L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine uptake in the left ventricle was quantified using CarimasTM software and compared between patients with and without Parkinson’s disease. The area under the receiver operating characteristic curve was used to evaluate the ability of the left ventricular mean standardized uptake value to discriminate between patients with Parkinson’s disease and those with other extrapyramidal syndromes. Seventy-six patients were included, of whom 52 were diagnosed with Parkinson’s disease. The mean L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine left ventricular mean standardized uptake value was lower in the Parkinson’s disease patients compared to the non- Parkinson’s disease patients (1.08 ± 0.21 vs. 1.24 ± 0.32, P = 0.015). The left ventricular mean standardized uptake value was able to discriminate between Parkinson’s disease and non- Parkinson’s disease patients (the area under the receiver operating characteristic curve = 0.641, P = 0.049). In conclusion, quantification of cardiac L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine uptake may be able to differentiate between patients with and without Parkinson’s disease. Validation of this finding in more substantial, prospective trials are warranted. |
| first_indexed | 2024-04-14T05:02:43Z |
| format | Article |
| id | doaj.art-819f30af107f4b49908462cd26663089 |
| institution | Directory Open Access Journal |
| issn | 1757-448X |
| language | English |
| last_indexed | 2024-04-14T05:02:43Z |
| publishDate | 2020-09-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Journal of Integrative Neuroscience |
| spelling | doaj.art-819f30af107f4b49908462cd266630892022-12-22T02:10:52ZengIMR PressJournal of Integrative Neuroscience1757-448X2020-09-0119348949410.31083/j.jin.2020.03.196[18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept studyJonathan Kuten, Adi Linevitz, Hedva Lerman, Nanette Freedman, Meir Kestenbaum, Tamara Shiner, Nir Giladi, Einat Even-Sapir01Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel;2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 6997801, Israel;3Movement Disorders Unit, Neurological Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv, 6423906, Israel;4Sagol School of Neurosciences, Tel-Aviv University, Tel-Aviv, 6997801, IsraelAutonomic involvement, including cardiac denervation, may precede the motor symptoms of Parkinson’s disease by several years. L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine is a positron emitter and a true analog of L-dopa, used in clinical practice to assess striatal dopaminergic integrity. The present study aimed to assess the feasibility of evaluating cardiac sympathetic denervation in Parkinson’s disease patients using L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine positron emission tomography/computed tomography. Patients referred for an L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine positron emission tomography/computed-tomography between July 2015 and May 2017 to evaluate striatal presynaptic dopaminergic integrity underwent a heart positron emission tomography scan following a brain positron emission tomography scan. L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine uptake in the left ventricle was quantified using CarimasTM software and compared between patients with and without Parkinson’s disease. The area under the receiver operating characteristic curve was used to evaluate the ability of the left ventricular mean standardized uptake value to discriminate between patients with Parkinson’s disease and those with other extrapyramidal syndromes. Seventy-six patients were included, of whom 52 were diagnosed with Parkinson’s disease. The mean L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine left ventricular mean standardized uptake value was lower in the Parkinson’s disease patients compared to the non- Parkinson’s disease patients (1.08 ± 0.21 vs. 1.24 ± 0.32, P = 0.015). The left ventricular mean standardized uptake value was able to discriminate between Parkinson’s disease and non- Parkinson’s disease patients (the area under the receiver operating characteristic curve = 0.641, P = 0.049). In conclusion, quantification of cardiac L-3,4-dihydroxy-6-[18F] fluoro-phenylalanine uptake may be able to differentiate between patients with and without Parkinson’s disease. Validation of this finding in more substantial, prospective trials are warranted.https://jin.imrpress.com/fileup/1757-448X/PDF/1601432747551-43610672.pdf|parkinson’s disease|positron emission tomography|myocardium|neuroimaging |
| spellingShingle | Jonathan Kuten, Adi Linevitz, Hedva Lerman, Nanette Freedman, Meir Kestenbaum, Tamara Shiner, Nir Giladi, Einat Even-Sapir [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study Journal of Integrative Neuroscience |parkinson’s disease|positron emission tomography|myocardium|neuroimaging |
| title | [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study |
| title_full | [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study |
| title_fullStr | [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study |
| title_full_unstemmed | [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study |
| title_short | [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study |
| title_sort | 18f fdopa pet may confirm the clinical diagnosis of parkinson s disease by imaging the nigro striatal pathway and the sympathetic cardiac innervation proof of concept study |
| topic | |parkinson’s disease|positron emission tomography|myocardium|neuroimaging |
| url | https://jin.imrpress.com/fileup/1757-448X/PDF/1601432747551-43610672.pdf |
| work_keys_str_mv | AT jonathankutenadilinevitzhedvalermannanettefreedmanmeirkestenbaumtamarashinernirgiladieinatevensapir 18ffdopapetmayconfirmtheclinicaldiagnosisofparkinsonsdiseasebyimagingthenigrostriatalpathwayandthesympatheticcardiacinnervationproofofconceptstudy |